PCSK9 and neuropathy, small fiber: ODYSSEY OUTCOMES did not identify an excess of neurocognitive events with alirocumab, and pooled trial reviews and meta-analyses consistently report neutral neurocognitive safety profiles for PCSK9 inhibitors, although these datasets were not powered for small-fiber neuropathy or subtle sensory changes.